Premium
Perspectives for new treatments at Alcon ‐ part 2
Author(s) -
RICH C
Publication year - 2012
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2012.3224.x
Subject(s) - presentation (obstetrics) , medicine , optometry , ophthalmology , diabetic retinopathy , retinal , surgery , diabetes mellitus , endocrinology
In an effort to continue to meet unmet medical needs for ophthalmology conditions Alcon continues to have a well developed pipeline of products in the Ophthalmology space. This presentation will give the audience an overview of how we identify a wide variety of potential products to develop and how we condense this list down to the final candidates that will establish our pipeline strategy. This process is conducted across the 3 main franchises of Alcon: Pharmaceuticals, Surgical and Vision Care. This presentation will review products in development in the area of Retina and this is an exciting area for Alcon with several projects in development for the treatment of a number of conditions. Alcon is conducting multiple projects in the area of vitreo‐retinal diseases including products for vitreolysis, dry and wet AMD, retinal vein occlusion and diabetic retinopathy. In the area of rare diseases Alcon currently has a program to evaluate the treatment of multifocal choroiditis. During this presentation we will discuss these programs on a high level and also discuss our approach to retina, which we see as a growing area within ophthalmology. The treatment of retinal conditions is still early in its evolution and Alcon looks forward to developing products that treat significant unmet medical needs in the area of Retina.